{"drugs":["Iopromide","Ultravist"],"mono":{"0":{"id":"923383-s-0","title":"Generic Names","mono":"Iopromide"},"1":{"id":"923383-s-1","title":"Dosing and Indications","sub":[{"id":"923383-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Angiography of arteries of extremity:<\/b> iopromide (300 mg iodine\/mL) INTRA-ARTERIAL INJECTION; usual volumes are 5 to 40 mL for subclavian or femoral artery and 25 to 50 mL for aortic bifurcation (distal runoff); MAX TOTAL DOSE 250 mL\/procedure<\/li><li><b>Aortography:<\/b> iopromide (370 mg iodine\/mL) INTRA-ARTERIAL INJECTION at volumes and rate proportional to the blood flow through the vessels of interest; MAX TOTAL DOSE 225 mL\/procedure<\/li><li><b>Arteriography of cerebral arteries:<\/b> iopromide (300 mg iodine\/mL) INTRA-ARTERIAL INJECTION; usual volumes are 3 to 12 mL for carotid arteries, 4 to 12 mL for vertebral arteries, and 20 to 50 mL for aortic arch injection in a simultaneous 4-vessel study; MAX TOTAL DOSE 150 mL\/procedure<\/li><li><b>Cardiac ventriculography:<\/b> iopromide (370 mg iodine\/mL) INTRA-ARTERIAL INJECTION at suggested volumes of 30 to 60 mL in the left ventricle with 3 to 14 mL in the right coronary artery and left coronary artery for coronary arteriography; MAX TOTAL DOSE 225 mL\/procedure<\/li><li><b>Computerized axial tomography:<\/b> iopromide 300 mg iodine\/mL given as 50 to 200 mL for bolus IV injection and 100 to 200 mL for rapid IV infusion; MAX TOTAL DOSE 200 mL (60 g iodine)\/procedure<\/li><li><b>Computerized axial tomography:<\/b> iopromide 370 mg iodine\/mL given as 41 to 162 mL for bolus IV injection and 81 to 162 mL for rapid IV infusion; MAX TOTAL DOSE 162 mL (60 g iodine)\/procedure<\/li><li><b>Computerized axial tomography of brain:<\/b> iopromide 300 mg iodine\/mL, given as 50 to 200 mL IV; MAX TOTAL DOSE 200 mL (60 g iodine)\/procedure<\/li><li><b>Computerized axial tomography of brain:<\/b> iopromide 370 mg iodine\/mL, given as 41 to 162 mL IV; MAX TOTAL DOSE 162 mL (60 g iodine)\/procedure<\/li><li><b>Coronary angiography:<\/b> iopromide (370 mg iodine\/mL) INTRA-ARTERIAL INJECTION; usual volumes are 3 to 14 mL in the right coronary artery and left coronary artery, and 30 to 60 mL in the left ventricle for ventriculography; MAX TOTAL DOSE 225 mL\/procedure<\/li><li><b>Digital subtraction angiography:<\/b> iopromide (150 mg iodine\/mL) INTRA-ARTERIAL INJECTION at suggested volumes of 6 to 10 mL for carotid arteries, 4 to 8 mL for vertebral arteries, 20 to 50 mL for aorta, and 2 to 20 mL for major branches of the abdominal aorta; MAX TOTAL DOSE 250 mL\/procedure.<\/li><li><b>Inferior vena cavogram:<\/b> iopromide (370 mg iodine\/mL) INTRA-ARTERIAL INJECTION at volumes and rate proportional to the blood flow through the vessels of interest; MAX TOTAL DOSE 225 mL\/procedure<\/li><li><b>Intravenous pyelogram:<\/b> iopromide (300 mg iodine\/mL), recommended dose approximately 300 mg iodine\/kg IV; MAX TOTAL DOSE 100 mL (30 g iodine)<\/li><li><b>Venography:<\/b> peripheral: iopromide (240 mg iodine\/mL) IV; use minimum volume needed to visualize the peripheral veins; MAX TOTAL DOSE 250 mL\/procedure<\/li><\/ul>"},{"id":"923383-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in children 2 years of age and younger<\/li><li><b>Computerized axial tomography:<\/b> (older than 2 years) iopromide 300 mg iodine\/mL; usual dose is 1 to 2 mL\/kg IV; MAX TOTAL DOSE 3 mL\/kg.<\/li><li><b>Computerized axial tomography of brain:<\/b> (older than 2 years) iopromide 300 mg iodine\/mL, usual dose is 1 to 2 mL\/kg IV; MAX TOTAL DOSE 3 mL\/kg.<\/li><li><b>Coronary angiography:<\/b> (older than 2 years) iopromide (370 mg iodine\/mL) INTRA-ARTERIAL INJECTION; usual dose of 1 to 2 mL\/kg; MAX TOTAL DOSE 4 mL\/kg.<\/li><li><b>Intravenous pyelogram:<\/b> (older than 2 years) iopromide 300 mg iodine\/mL, usual dose is 1 to 2 mL\/kg IV; MAX TOTAL DOSE 3 mL\/kg<\/li><\/ul>"},{"id":"923383-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> use the lowest necessary dose<\/li><li><b>pheochromocytoma:<\/b> use the lowest necessary dose<\/li><\/ul>"},{"id":"923383-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Angiography of arteries of extremity<\/li><li>Aortography<\/li><li>Arteriography of cerebral arteries<\/li><li>Cardiac ventriculography<\/li><li>Computerized axial tomography<\/li><li>Computerized axial tomography of brain<\/li><li>Coronary angiography<\/li><li>Digital subtraction angiography<\/li><li>Inferior vena cavogram<\/li><li>Intravenous pyelogram<\/li><li>Venography: peripheral<\/li><\/ul>"}]},"2":{"id":"923383-s-2","title":"Black Box Warning","mono":"<b>Injection (Solution)<\/b><br\/>Not for Intrathecal Use: Inadvertent intrathecal administration may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema.<br\/>"},"3":{"id":"923383-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923383-s-3-9","title":"Contraindications","mono":"<ul><li>intrathecal use<\/li><li>pediatric patients, prolonged fasting or laxative use before administration; risk for acute renal failure<\/li><\/ul>"},{"id":"923383-s-3-10","title":"Precautions","mono":"<ul><li>anaphylactoid reactions, life-threatening or fatal, may occur; increased risk with previous reaction to contrast agent, iodine sensitivity, known allergies, allergic disorders, or other hypersensitivities<\/li><li>blood-brain barrier disruption; accumulation of contrast in brain may occur<\/li><li>cardiovascular reactions, severe (eg, cardiac arrest, pulmonary edema, hypotensive collapse, shock), acute or delayed, some fatal; increased risk with congestive heart failure, severe renal impairment, combined renal and hepatic disease or renal and cardiac disease, especially with large\/repetitive doses; monitoring patients with cardiovascular disease recommended<\/li><li>extravasation may cause tissue necrosis\/compartment syndrome; increased risk in patients with severe arterial or venous disease<\/li><li>homocystinuria; increased risk for thrombosis and embolism; avoid angiography<\/li><li>hyperthyroidism or autonomously functioning thyroid nodule; thyroid storm has been reported<\/li><li>kidney injury, acute (including renal failure); may occur; increased risk with dehydration, elderly patients, previous renal insufficiency, diabetes mellitus, congestive heart failure, advanced vascular disease, concomitant nephrotoxic or diuretic medications, multiple myeloma\/paraproteinemia, and repetitive\/large doses of drug<\/li><li>pediatric patients; increased risk for adverse events with asthma, medication sensitivity, allergies, cyanotic and acyanotic heart disease, congestive heart failure, or serum creatinine greater than 1.5 mg\/dL; dose adjustment required<\/li><li>pheochromocytoma; hypertensive crisis may occur; monitoring recommended; dosage adjustment may be necessary<\/li><li>radiation exposure increased; evaluate risk prior to use<\/li><li>renal impairment, with normal blood-brain barrier; blood-brain barrier disruption and accumulation of contrast in brain may occur dosage adjustment may be necessary<\/li><li>sickle cell disease, particularly homozygous disease; increased risk of sickling<\/li><li>thromboembolic complications (eg, organ damage, ischemia, thromboembolism, organ failure, myocardial infarction, stroke, brachial plexus palsy, chest pain, sinus arrest, hepatorenal function abnormalities) may occur with angiography; monitoring recommended<\/li><li>thrombosis, phlebitis, severe ischemia, local infection, venous thrombosis, venous system obstruction; caution during venography<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"923383-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"923383-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"923383-s-4","title":"Drug Interactions","sub":{"0":{"id":"923383-s-4-13","title":"Contraindicated","mono":"<ul>Metformin (theoretical)<\/ul>"},"2":{"id":"923383-s-4-15","title":"Moderate","mono":"<ul><li>Iocetamic Acid (probable)<\/li><li>Iopanoic Acid (probable)<\/li><li>Ipodate (probable)<\/li><li>Tyropanoate Sodium (probable)<\/li><\/ul>"}}},"5":{"id":"923383-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (1.6%), Vasodilatation (2.6%)<\/li><li><b>Dermatologic:<\/b>Injection site reaction (3.7%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (3.7%), Taste sense altered (1.3%), Vomiting (1.9%)<\/li><li><b>Musculoskeletal:<\/b>Backache (1.9%)<\/li><li><b>Neurologic:<\/b>Headache (4%)<\/li><li><b>Renal:<\/b>Urgent desire to urinate (1.8%)<\/li><li><b>Other:<\/b>Pain (1.4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac arrest, Complete atrioventricular block (up to 1%), Coronary artery thrombosis (up to 1%), Hypotension (up to 1%), Shock, Syncope (up to 1%)<\/li><li><b>Musculoskeletal:<\/b>Compartment syndrome<\/li><li><b>Neurologic:<\/b>Disturbance in speech (up to 1%)<\/li><li><b>Renal:<\/b>Nephrotoxicity, Renal failure<\/li><li><b>Respiratory:<\/b>Pulmonary hypertension (up to 1%)<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"923383-s-6","title":"Drug Name Info","sub":{"0":{"id":"923383-s-6-17","title":"US Trade Names","mono":"Ultravist<br\/>"},"2":{"id":"923383-s-6-19","title":"Class","mono":"Radiological Non-Ionic Contrast Media<br\/>"},"3":{"id":"923383-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923383-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923383-s-7","title":"Mechanism Of Action","mono":"Systemic: Organic iodine compounds block x-rays as they pass through the body, thereby allowing the body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. The degree of opacity produced by these compounds is directly proportional to the total amount (concentration and volume) of the iodinated contrast agent in the path of the x-rays.    After intravascular administration, iopromide makes opaque those vessels in its path of flow, allowing visualization of the internal structures until significant hemodilution occurs.  <br\/>"},"8":{"id":"923383-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"923383-s-8-26","title":"Excretion","mono":"Systemic: Fecal: 2%; Renal: 97% unchanged <br\/>"},"4":{"id":"923383-s-8-27","title":"Elimination Half Life","mono":"Systemic: 6.2 h <br\/>"}}},"9":{"id":"923383-s-9","title":"Administration","mono":"<b>General Information<\/b><br\/><ul><li>do not administer intrathecally<\/li><li>adequately hydrate patient prior to and following administration<\/li><li>warm iopromide to body temperature shortly before administration to improve tolerability and ease of injection<\/li><\/ul>"},"11":{"id":"923383-s-11","title":"How Supplied","mono":"<b>Ultravist<\/b><br\/>Injection Solution: 311.7 MG\/ML, 498.72 MG\/ML, 623.4 MG\/ML, 768.86 MG\/ML<br\/>"}}}